Programme agreements

The mRNA technology transfer programme supported by WHO, MPP and partners, is designed to encourage the sustainable development of mRNA vaccines and therapeutics against COVID-19 and other diseases that threaten low- and middle-income countries.


New consortium working to boost vaccine production in South Africa (Published 30 July 2021)

Consortium to establish the first COVID mRNA vaccine technology transfer hub in South Africa

The Medicines Patent Pool (MPP), the World Health Organization (WHO), Afrigen, Biovac, SAMRC and Africa CDC have signed a letter of intent to address the global imbalance of manufacturing capacity for COVID-19 vaccines. The consortium will work together to establish the South African mRNA technology transfer hub that will allow for greater and more diversified vaccines manufacturing capability, strengthen African regional health security, and respond more equitably to the current COVID-19 pandemic and future pandemics.

Share page: